6-Bromo-2-(2,2-dimethyltetrahydropyran-4-yl)chroman-4-one | 1212019-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-Bromo-2-(2,2-dimethyltetrahydropyran-4-yl)chroman-4-one
• 英文别名: 6-bromo-2-(2,2-dimethyloxan-4-yl)-2,3-dihydrochromen-4-one
• CAS: 1212019-59-4
• 化学式: C₁₆H₁₉BrO₃
• 分子量: 339.229
• InChiKey: GCNLOJMBJOJTLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Bromo-2-(2,2-dimethyltetrahydropyran-4-yl)chroman-4-one 在 titanium(IV) tetraethanolate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 70.5h， 生成 6-Bromo-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-4'-methylspiro[chroman-4,2'-imidazole]-5'(1'H)-thione
  参考文献：
  名称：

  Compounds and their use as BACE Inhibitors

  摘要：

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。

  公开号：

  US20120165347A1
• 作为产物：
  描述：

  2,2-二甲基四氢吡喃-4-甲醛 、 2-羟基-5-溴苯乙酮 在 四氢吡咯 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以76%的产率得到6-Bromo-2-(2,2-dimethyltetrahydropyran-4-yl)chroman-4-one
  参考文献：
  名称：

  Compounds and their use as BACE Inhibitors

  摘要：

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。

  公开号：

  US20120165347A1

文献信息

• COMPOUNDS AND THEIR USE AS BACE INHIBITORS
  申请人：ASTRAZENECA AB

  公开号：US20160184303A1

  公开（公告）日：2016-06-30

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）化合物及其制药组合物。此外，本发明还涉及用于治疗和/或预防与Aβ相关的病理学，例如唐氏综合症、β淀粉样蛋白病变（如但不限于脑淀粉样血管病变或遗传性脑出血）、与认知障碍相关的疾病（如但不限于轻度认知障碍）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与疾病相关的神经退行性疾病（如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆、早老性痴呆、老年性痴呆和与帕金森病、进行性核上性麻痹或皮质基底节变性相关的痴呆）。
• [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
  申请人：ASTRAZENECA AB

  公开号：WO2012087237A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

  本发明涉及公式（I）化合物及其制药组合物。此外，本发明涉及治疗和/或预防与Αβ相关的病理学，如唐氏综合症，β-淀粉样血管病，如但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症等疾病相关的神经退行性。包括混合血管性和退行性起源的痴呆症，早老性痴呆症，老年痴呆症和与帕金森病相关的痴呆症的治疗方法。
• Inhibitors Of Beta-Secretase
  申请人：Dillard Lawrence W.

  公开号：US20110218192A1

  公开（公告）日：2011-09-08

  The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.

  本发明涉及以下结构式所表示的化合物或其药学上可接受的盐。还描述了包含由结构式（I）所表示的化合物的药物组合物和使用这些化合物抑制需要此类治疗的受体中的BACE活性的方法。
• Compounds and their use as BACE inhibitors
  申请人：Astrazeneca AB

  公开号：US08865911B2

  公开（公告）日：2014-10-21

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）化合物及其药物组合物。此外，本发明涉及治疗和/或预防与Aβ相关的病理状况，如唐氏综合症、β-淀粉样物质血管病，如但不限于脑淀粉样物质血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI）、阿尔茨海默病、记忆力下降、与阿尔茨海默病相关的注意力缺陷症状，与疾病相关的神经退行性疾病，如阿尔茨海默病或痴呆症，包括混合血管性和退行性起源的痴呆、早老性痴呆、老年性痴呆和与帕金森病、进行性核上性麻痹或皮质基底节变性相关的痴呆的治疗方法。
• INHIBITORS OF BETA-SECRETASE
  申请人：Dillard Lawrence W.

  公开号：US20130317014A1

  公开（公告）日：2013-11-28

  The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.

  本发明涉及以下结构式所代表的化合物：或其药学上可接受的盐。还描述了包括结构式（I）所代表的化合物的药物组合物以及使用这些化合物抑制需要此类治疗的受体中的BACE活性的方法。